Now, in order to support breakeven and eventual profit, the company is shifting to focus on key programs and usher them through the final stages of development. Top institutional shareholders of Moderna include Baillie Gifford & Co. (11.05%), FMR LLC (4.52%), State Street Corp (4.38%) and Geode Capital Management LLC (1.84%). Insiders that own company stock include Stephane Bancel, Noubar Afeyan, Stephen Hoge, Shannon Thyme Klinger, Juan Andres, James M Mock, Arpa Garay and David W Meline. Moderna scored higher than 92% of companies evaluated by MarketBeat, and ranked 107th out of 964 stocks in the medical sector.

Vaccine maker stocks fall after conspiracy theory-spreading RFK Jr. tapped to lead health department

Finally, Swiss National Bank raised its stake in Moderna by 0.3% during the third quarter. Swiss National Bank now owns 966,800 shares of the company’s stock worth $64,611,000 after acquiring an additional 3,200 shares during the period. Institutional investors and hedge funds own 75.33% of the company’s stock. But if you’re ready to hold on for a few more years, it could turn just2trade broker review out to be a wise move.

Moderna’s bad news

And the biotech aims to file for regulatory approval of three potential products by the end of the year — a next-generation coronavirus vaccine, a combined influenza/coronavirus vaccine, and an RSV vaccine for younger high-risk adults. Last month, the company revised coronavirus vaccine revenue downward due to lower lexatrade review sales. And in its update this week, the biotech made significant changes to its strategy. Moderna plans to cut annual research and development (R&D) spending by more than $1 billion starting in 2027 and discontinue five programs — and it forecast that it would break even in 2028 instead of 2026. This past week saw better stock news for Moderna, as shares rebounded 12% from last week, rising to $41.11 Friday, from $36.85 on November 15.

Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Moderna Inc. is actively working to develop a range of pharmaceutical solutions and vaccines and to increase its strategic alliances. The company has seen success in its innovative mRNA technologies, and its growing partnerships have given them an edge over its competitors. GOLDEN, Colo.–(BUSINESS WIRE)–PharmaJet needle-free technology enhances mRNA vaccine immune response and has been successfully adopted into multiple vaccine development programs. Shares of vaccine makers fell on reports that President-elect Donald Trump is expected to nominate Robert F. Kennedy Jr., a prominent vaccine skeptic, to lead the Department of Health and Human Servic… Stocks linked to vaccine developers such as Moderna, Pfizer and Novavax tanked in the leadup to market close Thursday, tumbling after reports surfaced that President-elect Donald Trump would select va…

Moderna Exec Downplays RFK Jr. Nomination To Be HHS Head

Moderna Inc. operates in multiple therapeutic areas, including infectious diseases, immuno-oncology, rare diseases, autoimmune diseases and cardiovascular diseases. Its product pipeline includes prophylactic vaccines, localized regenerative therapeutics, cancer vaccines, systemic secreted therapeutics, intratumoral immuno-oncology and systemic intracellular therapeutics. The company is also developing vaccines and therapeutics for other infectious diseases, such as influenza, hMPV+PIV3, respiratory syncytial virus, endemic HCoV, cytomegalovirus, human immunodeficiency virus, herpes simplex virus, Epstein-Barr virus and varicella-zoster virus. Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Despite this week’s relatively good news, Moderna shares are down 48% year-over-year, having closed at $78.17 on November 22, 2023, no small factor in the company mapping out its comeback. But the stock has upside potential, he added, should Moderna deliver on plans to bring 10 pipeline candidates to approvals, up from the current two (SpikeVax and respiratory syncytial virus RSV vaccine mRESVIA, the latter approved in May).

Moderna shares recently were up 7% Friday afternoon and have added 11% in the last two sessions. Still, Moderna shares are down almost 60% this year amid waning demand for COVID-19 vaccines. The company just released its latest results and revenue totaled $6.8 billion for 2023, coming mainly from its COVID vaccine. That’s down sharply from the $19.3 billion in sales Moderna tokenexus recorded in 2022.

The 10 include three of Moderna’s five respiratory vaccines with positive Phase III results, which the company expects to submit for approval this year. Jefferies Financial Group decreased their target price on Moderna from $65.00 to $55.00 and set a “hold” rating for the company in a research note on Tuesday, October 15th. Royal Bank of Canada restated a “sector perform” rating and set a $75.00 price objective on shares of Moderna in a research report on Thursday, September 19th. Deutsche Bank Aktiengesellschaft raised Moderna from a “sell” rating to a “hold” rating and dropped their target price for the stock from $85.00 to $80.00 in a research report on Wednesday, August 7th. Sanford C. Bernstein assumed coverage on shares of Moderna in a report on Thursday, October 17th. They set a “market perform” rating and a $55.00 price target for the company.

• Lowering its R&D expenses and slashing certain programs will result in fewer products launched in the next few years.
• Moderna (MRNA 3.19%) was a top stock to own during the early stages of the pandemic.
• MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on…
• Moderna has a lot of trials going on and may have a lot of potential sources of revenue in the future.

Trending News

Moderna (MRNA) shares surged further Friday, a day after a senior executive made bullish comments at a healthcare conference about the vaccine maker’s pipeline and cash position. For investors who make Moderna a reasonably sized part of a diversified portfolio, I think the stock is a buy today. As Moderna brings more products to the market, there will be additional opportunities to add to the position over time. Moderna approaches the development of vaccines and therapeutics using Messenger RNA (mRNA) technology. Put very simply, a vaccine utilizing mRNA technology teaches the body to make its own medicine.

Moderna, Inc. (NASDAQ:MRNA) Position Increased by Swedbank AB

It has been around four years since COVID crashed the stock market, albeit temporarily. The pandemic sent the healthcare industry into a panic, with vaccines from Moderna and Pfizer providing relief and stability to global economies. But odds are that in five years, COVID vaccine revenue will be minimal at best for Moderna. If Moderna can replicate its COVID-19 success with other respiratory viruses like the flu and RSV, there’s a case to be made that shareholders will be rewarded over time.